TABLE 3.

First-run interlaboratory reproducibility results for 99 isolates of P. aeruginosa from CF patients

Antimicrobial(s)a	% with broth microdilution MIC of:		% with disk zone size of:		% with Etest MIC of:
	±1 log2 dilution	±2 log2 dilutions	±3 mm	±6 mm	±1 log2 dilution	±2 log2 dilutions
Amikacin	92.9	99.0	84.0	97.9	89.6	99.0
Gentamicin	93.9	99.0	80.9	96.8	82.1	92.6
Tobramycin	90.9	100.0	70.2	97.9	91.3	97.8
Ticarcillin	84.8	96.0	71.7	85.9	84.6	91.2
Ticarcillin-clavulanate	86.9	93.9	76.3	87.1	86.8	90.1
Piperacillin	85.9	91.9	69.6	79.3	84.8	89.1
Piperacillin-tazobactam	81.8	89.9	61.3	80.6	80.9	89.4
Ceftazidime	85.9	94.9	69.9	84.9	80.0	87.4
Aztreonam	88.9	94.9	68.8	90.3	82.8	89.7
Ciprofloxacin	98.0	100.0	66.3	92.5	71.0	89.9
Imipenem	85.9	96.0	77.4	89.2	87.6	93.3
Meropenem	84.8	98.0	69.7	88.8	77.3	92.4
Allb	88.4	96.1	72.2	89.3	83.2	91.8

^aTicarcillin-clavulanate, 2 μg/ml; piperacillin-tazobactam, 4 μg/ml. 

^bMean values.